We hypothesized that abnormal oxidative stress in chronic heart failure (CHF) could be related to endothelial damage and platelet activation, and that the vasodilating β-blocker carvedilol would have beneficial effects on these processes compared with a selective non-vasodilating cardioselective β-blocker, bisoprolol. We therefore assessed the effects of introducing carvedilol and bisoprolol in a prospective manner on indices of oxidative stress [lipid hydroperoxides (LHP)], endothelial damage [von Willebrand factor (vWf)], platelet activation (soluble P-selectin) and coagulation (fibrinogen) and their inter-relationships in stable outpatients with CHF in sinus rhythm. We recruited 46 patients [23 male; age 64 + − 13 years (mean + − S.D.); range 38-85 years] with CHF. Baseline levels of serum LHP (P < 0.002), plasma vWf (P < 0.001) and soluble P-selectin (P = 0.02), but not fibrinogen (P = 0.16), were higher in CHF patients compared with 22 age-and sex-matched healthy controls. After treatment for 2 months, systolic blood pressure fell in both arms of the study (both P < 0.01), but there were no statistically significant (defined as P < 0.01) decreases in LHP, vWf, fibrinogen or soluble P-selectin levels with either carvedilol or bisoprolol. In conclusion, patients with CHF have increased levels of plasma LHP and vWf, indicating increased oxidative stress and endothelial damage respectively. Contrary to the proposed antioxidative effects of carvedilol, initiating and titrating such therapy did not result in a reduction in levels of LHP in CHF.
INTRODUCTION
A unifying concept in the pathophysiology of chronic heart failure (CHF) remains elusive. The important roles of neurohormonal activation, particularly sympathetic nervous system [1] and renin/angiotensin/aldosterone system [2, 3] are recognized. Indeed, the knowledge of deleterious effects of chronic elevation of neurohormones in CHF has enabled angiotensin-converting-enzyme inhibitors (ACE-Is) and β-adrenoceptor antagonists (β-blockers) to be used for the treatment of CHF, with beneficial effects on mortality and morbidity [4] [5] [6] [7] [8] [9] .
The involvement, relationship and contribution of endothelial damage and oxidative stress to the pathophysiology of CHF are less well established. Increased circulating levels of catecholamines in CHF, for example, may lead to endothelial damage and promote generation of superoxide radicals [10, 11] . Indeed, cross-sectional studies [10] [11] [12] [13] [14] have demonstrated abnormal oxidative stress in CHF, as assessed by measurement of lipid hydroperoxides (LHP) [10, 12] , whereas other studies have reported endothelial dysfunction, as assessed by flow-mediated dilatation [13] , endothelial damage and platelet activation, as reflected by abnormal levels of plasma markers, such as von Willebrand factor (vWf) and soluble P-selectin respectively, and fibrinogen in CHF [14] .
Furthermore, drugs which can potentially modulate abnormal oxidative stress in CHF may be important. For example, the non-selective β-blocker carvedilol has been shown in previous laboratory and small clinical studies to have additional properties that include oxidative stress reduction [15, 16] . This ancillary effect of carvedilol has been postulated to be one of the mechanisms for the clinical benefits of this agent in reducing mortality and morbidity in CHF [17, 18] , but this benefit has also been seen with other β-blockers [19] . Indeed, an antioxidant effect similar to carvedilol has not been described with the once-daily second-generation β-1 selective β-blocker bisoprolol, although this agent has also been shown to be beneficial in clinical trials [19] . The 'additional' properties of carvedilol (such as antioxidant and vasodilatory effects) have been the rationale of an ongoing comparison between carvedilol and metoprolol, a cardioselective β-blocker, in CHF in the Carvedilol and Metoprolol European heart failure Trial (COMET) [20] .
We hypothesized that abnormal oxidative stress in CHF is related to endothelial damage and platelet activation, and that the vasodilating β-blocker carvedilol would have beneficial effects on these processes compared with a selective non-vasodilating cardioselective β-blocker, bisoprolol. We therefore assessed the effects of introducing carvedilol and bisoprolol on indices of oxidative stress (LHP), endothelial damage (vWf), platelet activation (soluble P-selectin) and coagulation (fibrinogen), and their inter-relationships, in stable outpatients with CHF in sinus rhythm.
METHODS

Patients
Patients with CHF and previously documented ischaemic heart disease (at coronary angiography) were eligible if they were greater than 18 years of age and had impaired left ventricular function documented as ejection fraction less than 40 % either by echocardiography, radionuclide imaging or left ventriculography. Patients were also on established ACE-I therapy (lisinopril) for more than 4 weeks or, if ACE-Is were not tolerated, on an angiotensin II receptor blocker (losartan). Exclusion criteria were the following: recent (< 3 months) decompensation of CHF or hospitalization with CHF; known contra-indication or intolerance to β-blocker therapy; recent (< 3 months) myocardial infarction or stroke, unstable angina or ventricular arrhythmias; chronic and systemic illnesses, including renal failure, liver failure, cancer and vasculitis; anticoagulant therapy, hormone replacement therapy or regular use of multivitamin supplements; and/or recent acute illness (< 1 month).
Eligible patients were randomly assigned to receive either bisoprolol or carvedilol in an open-label manner. Treated patients underwent three treatment phases following the baseline screening visit: (i) a 2 week initial 'run-in' phase to ensure patients remained stable on their current medical therapy, which included an ACE-I or, in cases of intolerance to ACE-I, an angiotensin II receptor blocker; (ii) an 8 week schedule during which patients were initiated on bisoprolol or carvedilol according to the manufacturer's instructions; and (iii) a 2 month maintenance phase. The β-blockers were titrated to the maximum recommended dose according to the manufacturer's instructions or until resting heart rate fell to 50 bpm or systolic blood pressure (BP) was lowered less than 90 mmHg. Thus bisoprolol was started at 1.25 mg once daily, and titrated to the next level after a minimum of 1 week to 2.5 mg once daily, then 3.75 mg once daily and 5 mg once daily. If tolerated well after 4 weeks, a further increase to 7.5 mg once daily for 4 weeks and then to a 10 mg maximum maintenance dose was performed. For carvedilol, this was started at 3.125 mg twice daily, and titrated to next level after a minimum of 2 weeks to 6.25 mg twice daily, then 12.5 mg twice daily and 25 mg twice daily. Systolic BP and diastolic BP was recorded in each subject following a minimum of 5 min rest.
Baseline results from patients with CHF were compared with those obtained from age-( + − 5 years) matched control subjects recruited from among healthy hospital staff and subjects attending hospital for hernia repairs, varicose vein procedures or other minor operations. All were free of diabetes and were without clinical features of cardiovascular, neoplastic, infective or connective tissue disease. The project had the approval of the research Ethics Committee of the West Birmingham Health Authority and informed consent was obtained from each participant.
Blood samples and assays procedures
Blood tests performed at baseline (pretreatment with β-blocker) and after 2 months maintenance therapy. Citrated plasma and serum were obtained from venous blood by centrifugation at 1000 g for 15 min at 4
• C. Aliquots were stored at − 70
• C to allow batch analysis. Soluble P-selectin and vWf were measured by ELISA on citrated plasma using commercial reagents (R&D Systems, Abingdon, Oxon., U.K., and Dako-Patts, Ely, Cambs., U.K. respectively). The unit for vWf is international unit (i.u.)/dl and was standardized by reference vWf from the National Institute for Biological Standards and Controls (South Mimms, Herts., U.K.). Serum LHP were chosen as marker of oxidative stress as it has been validated in previous studies involving CHF patients [10, 12] . LHP were analysed by the ferrous oxidation of the colorimetric dye xylenol orange in conjunction with the specific hydroperoxide reductant triphenylphosphine, as described previously [21] . Plasma fibrinogen (g/l) was measured by a modified Clauss technique on a Pacific Haemostasis (Huntersville, NC, U.S.A.) coagulometer and reagents from Alpha Laboratories (Eastleigh, Hants., U.K.). Intra-assay coefficients of variation for all assays (soluble P-selectin, vWf, LHP and fibrinogen) were < 5 %, inter-assay variances were < 10 %. The laboratory analyses were performed blinded (B. S. P. C. and A. D. B.) to the patients' clinical and treatment details.
Power calculations, analysis of data and statistics
The major biochemical end point we sought was a reduction in levels of LHP of approx. 20 %. However, without the benefit of other data indicating expected raised levels in CHF compared with controls, a formal a priori power calculation is impossible. Therefore we based our power calculation on the expected effect of introduction of β-blocker therapy to reduce systolic BP by approx. one-half of an S.D. (assuming equal variances) as a crude measure of a haemodynamically significant dose of the drug. Recognizing the inherent variability in the assay of LHP [21] , we sought confidence at P < 0.01. In order to achieve this for a one-sided paired Student's t test or Wilcoxon's method of P < 0.01 and a 1-β of 0.80, the power calculation required 20 patients per group [22] . However, to ensure good data in the possible light of drop-outs, we aimed to recruit an excess of patients in each of the two arms of the study. Co-incidentally, all drop-outs occurred in the cardevilol arm of the study and we obtained our required data set of paired data in at least 20 subjects per arm of the study. We also recruited a number of apparently healthy controls to provide a perspective for the laboratory markers. The data were generated purely for comparison and no original hypothesis was being tested. However, the numbers provided sufficient power at 1-β = 0.80 and a one-sided P < 0.05 for a difference of 0.561 of a S.D. [22] .
Data proven by normality testing (e.g. Shapiro-Wilks) to be normally distributed (results not shown) are expressed as means + − S.D. Data non-normally distributed are expressed as median and inter-quartile range. Baseline data between patients and controls were analysed by the unpaired Student's t test or the Mann-Whitney U test. Serial data (pre-and post-treatment) were analysed by paired Student's t test for parametric data and by paired Wilcoxon test for non-parametric data to compare variables at baseline and 2 months. Data were entered into a computerized database and analysed using computerbased statistical software (Minitab-12, Windows 98; 
RESULTS
We recruited 50 patients into the study between June 1999 and June 2000: 26 patients received bisoprolol and 24 received carvedilol. Most patients (n = 40) were taking lisinopril as their ACE-I, whereas the remainder were stabilized on losartan, due to a previous ACE-Iinduced cough. The median total daily maintenance dose for carvedilol and bisoprolol were 25 mg and 5 mg respectively. However, four patients, all in the carvedilol arm of the study, withdrew consent: one with exacerbation of psoriasis, one had worsening of CHF symptoms, and two withdrew because of undefined symptoms of lethargy. Thus the present analysis is based on a completed dataset of 46 patients [23 male; age 64 + − 13 years (mean + − S.D.); range 38-85 years] ( Table 1 ). There were no statistically significant differences in mean age, gender ratio and presence of co-morbid factors, including smoking, diabetes, hypertension, previous myocardial infarction and hyperlipidaemia, between both treatment groups ( Table 1) .
Cross-sectional comparisons
There was no statistically significant difference in mean age or gender ratio between patients and controls. Mean baseline levels of LHP in the whole cohort of CHF patients was significantly higher than controls (P = 0.0015). Similarly, mean levels of plasma vWf (P < 0.001) and soluble P-selectin (P = 0.02), but not fibrinogen (P = 0.16), were higher in CHF patients compared with controls ( Table 2 ). All the individual differences exceed results not shown). There were no statistically significant differences in mean baseline LHP, vWf, soluble P-selectin and fibrinogen levels between the two treatment arms of the study (all P values were not significant; Table 3 ).
Effects of treatment
There was a significant reduction in mean systolic BP levels in both groups after treatment for 2 months with carvedilol or bisoprolol (all P < 0.01), indicating an appropriate drug effect (Table 3 ). There was no statistically significant (defined as P < 0.01) reduction of LHP in the patients receiving bisoprolol (paired Wilcoxon test P = 0.025, with the 95 % confidence interval for the median difference of LHP being − 0.1472 to 4.4042 µmol/l). There was no significant reduction in median levels of LHP in the carvedilol arm of the study (P = 0.38), with the 95 % confidence interval for the median difference of LHP being − 0.7906 to 3.14 µmol/l. There were no significant changes in mean vWf, fibrinogen and soluble P-selectin levels (Table 3 ). There were no significant correlations between the change in BP and any of the measured indices (Spearman, P value was not significant; results not shown). 
DISCUSSION
In recent years, β-blockers have come to be accepted as standard therapy for CHF [7] , in addition to ACE-I and diuretics [8, 9] . Carvedilol, a relatively new non-selective β-blocker, has been studied extensively [23, 24] and when the magnitude of mortality reductions were compared, carvedilol initially appeared to be superior to the mortality reduction seen with the second-generation β-1-selective β-blockers metoprolol and bisoprolol, although this has certainly not been conclusively proven in a headto-head comparison [19, [23] [24] [25] [26] [27] . This supposed difference in β-blocker properties is therefore being tested in the COMET study [20] , with the direct comparison between carvedilol and metoprolol in CHF. Some of the reasons for the improvement in survival have been attributed to supposed additional properties of carvedilol, such as antioxidative effects, as suggested by experimental data using high concentrations of this drug [17, 18] . However, whether or not this really matters in the clinical setting (for example, in patients with CHF, as in the present study) has not been shown conclusively.
Oxidative stress is a condition in which oxidant metabolites exert toxic effects because of their increased production or an altered cellular mechanism of protection [28] . There are various ways of measuring oxidative stress in vivo, but we chose to measure serum levels of LHP, because of their proven reliability and previous associations with CHF [10, 12] . Other indices of antioxidant status, including vitamins, glutathione peroxidase, total antioxidant capacity, thiobarbituric acid reactive substances and 9-11 linoleic acid ratio, all have various limitations [21, [28] [29] [30] and do not have the same clinical data as that seen with LHP for CHF.
The present study largely confirms the observations of significantly higher levels of oxidative stress in CHF, as well as the lack of effect of β-blockers on haemostastic markers [14] , although, in the present study, we have additionally measured vWf as a measure of endothelial damage. Some relationship between the endothelial damage seen in CHF and abnormal oxidative stress may therefore exist. Nevertheless, there are many ways of assessing endothelial damage/dysfunction and all have their limitations. Certainly, some workers would suggest that endothelial dysfunction is a dynamic process and should only be measured by flow-(or acetylcholine) mediated vasodilatation. However, vWf is an established marker of endothelial damage with thrombotic and prognostic implications (for a review, see [31] ) and, in atherosclerosis, an inverse relationship between antioxidant status and vWf has been reported [29] . Nevertheless, the true relationship between oxidative stress, endothelial damage and CHF is still unknown, although there is ample evidence that oxidative stress is involved in the pathogenesis of atherosclerosis, endothelial damage, platelet aggregation and CHF [32, 33] . It is currently thought that excessive production of superoxide may reduce synthesis of endothelium-derived relaxation factor (EDRF) or nitric oxide (NO), while stimulating the release of endothelins [34] [35] [36] [37] . Recent data have also shown a close link between apoptosis and oxidative stress [18] .
Carvedilol has been shown previously in experimental and animal models to reduce oxidative stress by inhibiting oxygen free-radical-mediated lipid peroxidation far more effectively than propanolol [15] and also to scavenge oxygen free radicals [16] . Kukin et al. [34] recently reported that both carvedilol and metoprolol reduced oxidative stress significantly and equally after 6 months therapy. Other β-blockers, such as propanolol [35] , have also been shown to reduce oxidative stress indirectly, although propanolol possesses neither cytotoxic nor superoxide-scavenging properties and its membranestabilizing effects may even lead to inhibition of superoxide generation [36] .
In the present study, we did not relate the changes in measured indices to catecholamines and neurohormonal markers or autonomic function. Indeed, Beanlands et al. [37] suggested that the reduction in oxidative stress by metoprolol at therapeutic doses might be due to its energy-sparing effect. The mechanism for this may be that elevated circulating plasma catecholamines and adrenergic stimulation leads to increased oxygen consumption, which can then lead to increased production of superoxide free radicals [38, 39] . β-Blockers also reduce heart rate and inotropy, thus reducing myocardial oxygen demand and consumption [40] . β-Blockers further prevent the stimulation of lipolysis by elevated circulating catecholamines [41] . Thus it is possible that β-blockers can reduce oxidative stress by improving the efficiency of oxygen utilization [42] . Thus oxidative stress reduction may not be a unique property of carvedilol, but may result from improvement in myocardial function or modulation of the sympathetic nervous system through the general effects of β-blockade, as seen with the patients treated with bisoprolol.
The present study was also limited by the crosssectional comparison between baseline indices and the open-label design and relatively small size of the intervention arms. Abnormal oxidative stress has also been observed in hypertension [30] , but, in the present study, there was no relation between LHP and BP or the degree of BP reduction with either agent. In the clinical trials, there was no significant BP decrease following the introduction of β-blockers. The clinical trials had very long follow-up (years) and it is possible that the long-term haemodynamic effects (improvement of left ventricular function etc.) resulted in no net effect on BP. In contrast, in the present short-term (2 months) mechanistic study, we aimed to achieve a pharmacologically significant dose of β-blocker, resulting in the reduction in BP seen. This response is at least supportive of drug compliance by our patients. Whether the changes in measured indices seen in the present study will translate into clinical effects will only be evident from results of clinical trials, such as COMET [20] . On the basis of the mechanistic effects tested, we speculate that there would be little clinical difference between carvedilol and a non-vasodilatory β-1 cardioselective agent (such as bisoprolol or metoprolol) in CHF.
In conclusion, patients with CHF have increased levels of plasma LHP and vWf, indicating increased oxidative stress and endothelial damage respectively. Contrary with the proposed antioxidative effects of carvedilol, initiating and titrating such therapy did not result in a reduction in levels of LHP in CHF.
